Elizabeth G. Demicco
Papers
3
Total Citations
23
H-Index
2
About
Elizabeth G. Demicco is a leading translational researcher whose work focuses on harnessing the immune system to combat human papillomavirus-associated oropharyngeal cancer (HPVOPC). Her major contributions center on pioneering the use of ADXS11-001, a live attenuated *Listeria monocytogenes*-based immunotherapy engineered to express the HPV E7 antigen. Through innovative “window of opportunity” clinical trials conducted prior to robotic surgery, Dr. Demicco has demonstrated that this therapeutic vaccination can effectively enhance HPV-specific T cell immunity within the tumor microenvironment and peripheral blood. Her landmark 2016 study (19 citations) provided critical early evidence that neoadjuvant immunotherapy can prime the immune system against viral oncogenes, while her subsequent 2018 work (2 citations) revealed dynamic changes in T cell receptor diversity following treatment. By establishing a paradigm for evaluating immunotherapies in the pre-surgical setting, Dr. Demicco has advanced our understanding of how to leverage foreign viral antigens to treat HPVOPC, which now accounts for nearly 75% of newly diagnosed oropharyngeal cancers. Her research continues to inform the development of targeted immunotherapeutic strategies for virally-driven malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3